Effects of olprinone on hemodynamics and oxygen delivery in pediatric cardiac surgery: Magnitude of effects and comparison to milrinone

Systematic review and meta-analysis of the efficacy of olprinone and MEFV gene in treating heart failure

“…Among the seven articles (21)(22)(23)(24)(25)(26)(27), the sample size of the articles with olprinone treatment was 1,287, and the sample size of the articles with other PDE inhibitors for treatment was 1,287. Additionally, the sample size of 7 included articles ranged from 10 to 951.…”

A Double-Blind Placebo-Controlled Study of the Effects of Olprinone, a Specific Phosphodiesterase III Inhibitor, for Preventing Postoperative Atrial Fibrillation in Patients Undergoing Pulmonary Resection for Lung Cancer

“…26 Low-dose atrial natriuretic peptide did not change BP and heart rates, but reduced WBC counts and CRP levels signifi cantly compared with the placebo group. 26 It has been reported that low-dose olprinone did not change hemodynamics 12,13 and exhibited significant antiinflammatory effects. [14][15][16][17] In this study, we investigated whether low-dose olprinone for 1 day could reduce the incidence of postoperative AF following pulmonary resection in patients with lung cancer.…”

“…It has been reported that the positive chronotropic eff ect of olprinone was less than that of milrinone, 12 and olprinone was eff ective in stabilizing hemodynamic parameters without aff ecting heart rate or BP and improving oxygen delivery compared with milrinone. 13 Orime et al 27 reported that low-dose olprinone (0.1 m g/kg/min) reduced pulmonary artery pressure and pulmonary capillary wedge pressure in patients undergoing coronary artery bypass graft ing. In the present study, patients in the olprinone group showed signifi cantly lower BNP levels aft er surgery compared with the placebo group.…”

“…10 PDE-III inhibitor cilostazol decreased total atrial conduction time in patients with peripheral artery disease, which may lead to the prevention of the development of AF. 11 In addition, it has been reported that low-dose olprinone did not change hemodynamics 12,13 and showed protective eff ects in various experimental injury models. [14][15][16][17] B-type natriuretic peptide (BNP) is secreted predominantly from the ventricles of the heart in response to volume expansion and pressure overload, and it is known to be a useful biomarker for the diagnosis of acute heart failure.…”

Assessment of the effect of two regimens of milrinone infusion in pediatric patients undergoing fontan procedure: A randomized study

“…Other studies found that the use of milrinone after CPB in pediatric patients undergoing Fontan procedure has no effect on the oxygen saturation, elevated pulmonary vascular resistance, central venous pressure, left atrial pressure, transpulmonary pressure gradient, and clinical outcomes after Fontan and the possible causes, (1) a limited amount of milrinone could enter into the pulmonary circulation at the initial stage as a result of a significant shunt to the systemic circulation through the fenestration, secondary-to-high pulmonary vascular resistance, and a lower concentration of milrinone in the pulmonary vascular wall; (2) the optimum concentration in the blood requires maintained infusion to be effective. [ 3 6 23 24 25 26 ]…”